P1.079. Real-World Adoption of Adjuvant Immunotherapy Following Trimodality Therapy for Esophageal Cancer: A National Cancer Database Analysis
Clicks: 1
ID: 325705
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
1 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #88 of 453 articles by views in diseases of the esophagus : official journal of the international society for diseases of the esophagus
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 453 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Topic Esophageal Cancer: Adjuvant and Neo-Adjuvant Therapies Background Following CheckMate 577 (CM577, 2021), adjuvant nivolumab was approved for patients with esophageal cancer (EC) and residual disease following trimodality therapy. As perioperative paradigms continue to evolve, early adoption patterns may inform implementation of future multimodality strategies. We evaluated adoption trends and factors associated with receipt of guideline-concordant adjuvant immunotherapy. Methods The National Cancer Database (NCDB) was queried for patients with resectable EC undergoing neoadjuvant chemoradiation and esophagectomy (2019-2023) who met criteria consistent with CM577 eligibility: cM0, pathological residual disease, and R0 resection. Patients who did not reach a 90-day postoperative landmark and those who received immunotherapy >120 days after surgery were excluded. Temporal implementation trends were assessed by using 2019 and 2020 as baseline comparators; the primary analysis of predictors of receipt of adjuvant immunotherapy was restricted to patients diagnosed between 2021–2023. High-volume centers were defined as those in the top quintile. A composite postoperative outcome of length of stay (LOS) >14 days or unplanned readmission was used as a surrogate for complications. A multivariable logistic regression model (MVA) was constructed to identify independent predictors of receiving adjuvant immunotherapy. Results Among 4,617 eligible patients, adjuvant immunotherapy use increased from 0.7% in 2019 to 52.5% in 2023 (Figure 1). The primary cohort (2021-2023) included 2,756 patients, of whom 50.7% (1,396) received adjuvant immunotherapy (IO+). The most common reason for non-receipt (IO-) was adjuvant immunotherapy not being part of planned treatment (86.1%, 1171/1360). No differences in administration were observed by age, race/ethnicity, clinical stage, insurance, Charlson-Deyo score, or income. Receipt was associated with shorter postoperative LOS (IO+: 8.0 days [IQR 7.0-10.0], IO-: 9.0 [7.0-13.0], P<0.001), adenocarcinoma histology (IO+: 89.5% [1249/1396], IO-: 85.9%, P=0.008), ypT3-4 (IO+: 46.3% [647/1396], IO-: 41.4% [563/1360], P<0.001), and residual nodal disease (IO+: ypN+ 47.9% [669/1396], IO-: 39.8% [541/1360], P<0.001). On MVA, ypN+ (adjusted OR 1.2, CI 1.0-1.5, P=0.026), squamous histology (adjusted OR 0.7, CI 0.6-0.9, P=0.045), ypM1 (adjusted OR 0.3, CI 0.1-0.8, P=0.019), and minimally-invasive approach (adjusted OR 1.6, CI 1.1-2.2, P=0.013) independently predicted immunotherapy (Figure 2). Conclusion Despite rapid uptake following approval, only half of potentially eligible patients received guideline-concordant adjuvant immunotherapy after trimodality therapy for esophageal cancer. Receipt of adjuvant immunotherapy was most strongly associated with perioperative and pathologic factors, rather than sociodemographic or facility-level characteristics, suggesting physician-level treatment selection rather than access limitations. As multimodality therapy strategies continue to evolve, understanding decision drivers and defining patients most likely to benefit from postoperative therapy will be essential to optimize guideline-concordant care.
| Reference Key |
openalex_W7203918316
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Zamaan Hooda, Ana Mccracken, Antonio Luna, M. Antonoff, Arlene Correa, Jenny Li, Steven Lin, Reza Mehran, David Rice, S SWISHER, Ara Vaporciyan, Garrett Walsh, Wayne Hofstetter, Ravi Rajaram, Kyle Mitchell |
| Journal | diseases of the esophagus : official journal of the international society for diseases of the esophagus |
| Year | 2026 |
| DOI |
10.1093/dote/doag077.227
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.